The only blood test to rule out “silent” subclinical acute kidney rejection


Healthcare Providers

Patients & Caregivers

TruGraf® is the first and only non-invasive test, validated and covered by CMS, as an alternative to surveillance biopsies to rule out “silent” subclinical acute rejection in transplant patients with stable graft function.

~35% of patients receive a surveillance biopsy in the first year

≥75% of patients who have surveillance biopsies show normal histology and the vast majority could have been spared an invasive procedure if tested with TruGraf®

≥20% of patients show subclinical acute rejection

TruGraf® aids physicians with non-invasive monitoring to rule out silent rejection.